Ashling Wahner

Zurletrectinib Receives Priority Review from NMPA for NTRK Gene Fusion+ Advanced Solid Tumors

May 2nd 2025

A priority review was granted to zurletrectinib in China for the treatment of patients with NTRK gene fusion–positive advanced solid tumors.

sBLA Submission Planned for Epcoritamab/Rituximab/Lenalidomide in R/R FL

May 2nd 2025

An sBLA seeking the approval of epcoritamab plus rituximab and lenalidomide for relapsed/refractory FL is planned to be submitted to the FDA.

Oncology Experts Highlight Top Takeaways From the 2025 AACR Annual Meeting

May 2nd 2025

Experts from across oncology specialties shared some of the most talked-about abstracts and discussions from the 2025 AACR Annual Meeting.

RP1 Plus Nivolumab Represents the Next Frontier of Oncolytic Virus–Based Therapy for Melanoma

May 2nd 2025

Anna C. Pavlick, BSN, MSc, DO, MBA, discusses data for RP1 plus nivolumab and the evolving treatment landscape in advanced melanoma.

Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH

May 1st 2025

Revisit Every OncLive On Air Episode From April 2025

May 1st 2025

Read a recap of the episodes of OncLive On Air that aired in April 2025.

Dr Simpkins on the Predictive Utility of Cyclin E1 for Azenosertib Response in Ovarian Cancer

April 30th 2025

Fiona Simpkins, MD, discusses key findings from the phase 2 DENALI trial evaluating azenosertib in patients with platinum-resistant ovarian cancer.

Dr Pimenta on Adipogenesis Defects Characteristic of Dedifferentiated Liposarcoma

April 30th 2025

Erica Maria Pimenta, MD, PhD, discusses a study investigating potential defects in molecular pathways involved in adipocyte-specific differentiation

Lung Cancer Experts Highlight the Significance and Limitations of ADCs

April 30th 2025

Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.

Early Ruxolitinib Initiation Increases Spleen Response Rates in Myelofibrosis

April 30th 2025

Patients with myelofibrosis who initiated ruxolitinib within 2 years of diagnosis achieved higher spleen response rates vs those with delayed initiation.

Dr Loong on the Efficacy of D3S-001 in KRAS G12C Inhibitor–Resistant NSCLC

April 30th 2025

Herbert H F Loong, MBBS(HK), PDipMDPath(HK), MRCP(UK), FRCP Edin, FHKCP, FHKAM(Medicine), FASCO, discusses the efficacy of D3S-001 in pretreated NSCLC.

Dr Sobh on the Effects of NSD2 Overexpression in Multiple Myeloma

April 29th 2025

Amin Sobh, PhD, discusses findings from a study investigating the immune surveillance–modulating capabilities of NSD2 overexpression in multiple myeloma.

Dr Cecchini on the Efficacy of Neoadjuvant Chemotherapy in CRC Liver Metastases

April 29th 2025

Michael Cecchini, MD, discusses the effects of neoadjuvant chemotherapy on tumor-infiltrating lymphocyte levels in colorectal cancer with liver metastases.

Dr Hanna on Elraglusib Plus Chemotherapy and Immunotherapy in Advanced Salivary Gland Cancer

April 29th 2025

Glenn J. Hanna, MD, discusses the efficacy of elraglusib plus chemotherapy with or without immunotherapy in patients with advanced salivary gland cancer.

Dr Pavlick on RP1 Plus Nivolumab in PD-1 Inhibitor–Pretreated Melanoma

April 29th 2025

Anna C. Pavlick, BSN, MSc, DO, MBA, discusses efficacy data with RP1 plus nivolumab in patients with melanoma who had progressed on PD-1–directed therapy.

Disease Features and Treatment Intolerance Inform Pirtobrutinib Use in Pretreated CLL: With Nicole Lamanna, MD

April 28th 2025

Dr Lamanna discusses how disease progression, treatment intolerance, and prior therapy exposure inform the decision to initiate pirtobrutinib in CLL.

Dr Haldar on Outcomes for NeoAg-VAX With or Without Pembrolizumab in MSS mCRC

April 28th 2025

S. Daniel Haldar, MD, discusses outcomes for NeoAg-Vax with or without pembrolizumab in MSS metastatic colorectal cancer.

Dr Tang on Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic ccRCC

April 28th 2025

Chad Tang, MD, discusses outcomes for metastasis-directed radiotherapy without systemic therapy in oligometastatic clear cell renal cell carcinoma.

Dr Sekeres on Next Steps for Evaluating the Association Between Smoking and MDS

April 25th 2025

Mikkael A. Sekeres, MD, discusses questions that remain unanswered regarding the association between smoking and MDS development and progression.

Dr Cortese on Potential Mechanisms for Improving CLL Outcomes With Venetoclax

April 25th 2025

Matthew Cortese, MD, MPH, discusses the rationale for an analysis of the immunologic activity of venetoclax in patients with chronic lymphocytic leukemia.